Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEVE UCCD LTE: 24-week phase 2b long-term extension of TEV-48574 in ulcerative colitis or Crohn's disease
MOH_2023-10-25_012736Phase 2Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of duvakitug in autoimmune colitis and Crohn's disease (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Maintenance of clinical remission in ulcerative colitis and Endoscopic response in Crohn's disease. Started Apr 2023; status: active, not recruiting.
02
Drugs
duvakitug
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on MOH_2023-10-25_012736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-25_012736.